Drugs / Premixed bioceramic MTA
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT06219824 | Nov 2024 → Nov 2025 overdue | dental caries, dental pulp disorder | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05928858 | Sep 2023 → Jun 2024 | dental pulp calcification | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT05314842 | Apr 2022 → Apr 2023 | dental caries | Sarah Abdelbar Mahmoud | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06288477 | Mar → May 2024 overdue | dental pulp disorder | October University for Modern Sciences and Arts | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Premixed bioceramic MTA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05314842 ↗ |
| Known as | NeoPUTTY | “NeoPUTTY® is composed of extremely fine inorganic tricalcium/dicalcium silicate powders in a water-free organic liquid and contains tantalum oxide as the radiopacifying agent.” NCT06288477 ↗ |
| Modality | Other / unclassified | “premixed ready for use bioceramic MTA” NCT06219824 ↗ |